30+ Presentations from Top Pharma at Drug Discovery Chemistry 2022

As in the past, speaker participation by industry was once again very strong, with presentations from AbbVie, Amgen, Astex Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Preview the 30+ presentations* below:

Upcycling Chemical Feedstocks to Escape DEL Flatland
Erika Crane, PhD, Senior Scientist II, Centralized Medicinal Chemistry; DEL Synthesis Lead, AbbVie, Inc.

A Cytokine Fragment Story
Justin Dietrich, PhD, Principal Research Scientist I, Fragment Based Drug Discovery and DNA-Encoded Library Technologies, AbbVie, Inc.

Applicability of Permeability Assays to bRo5 Compounds
Edward Price, PhD, Senior Scientist, Drug Metabolism and Pharmacokinetics, AbbVie, Inc.

Evaluating RIBOTAC Technology for Targeted RNA Degradation
Ryan Potts, PhD, Executive Director and Head, Induced Proximity Platform, Amgen, Inc.

Enabling New E3 Ubiquitin Ligases for Targeted Protein Degradation
Ryan Potts, PhD, Executive Director and Head, Induced Proximity Platform, Amgen, Inc.

A MedChem Look-Back on the Discovery of Sotorasib, G12CKRAS Inhibitor
Ryan P. Wurz, PhD, Principal Scientist, Medicinal Chemistry, Amgen, Inc.

Astex Pharmaceuticals
Fragment-to-Market Discovery of the Pan-FGFR Inhibitor Balversa (Erdafitinib)
Valerio Berdini, Director, Computational Chemistry, Astex Pharmaceuticals

Mass Spectrometry-Based Chemical Biology and Proteomics Methods for Selectivity Profiling of Compounds
Ghaith Hamza, PhD, Senior Proteomics Scientist, Discovery Sciences, AstraZeneca Pharmaceuticals

Target Deconvolution Using Compressed Cellular Thermal Shift Assay (cCETSA) Influences Key Project Decisions
Aarti Kawatkar, Associate Principal Scientist, Chemical Biology & Proteomics, AstraZeneca R&D

Applying cryo-EM for RET Signalling Drug Discovery
Jenny Sandmark, PhD, Associate Principal Scientist, Drug Discovery, AstraZeneca R&D

Chemoproteomic Profiling with Photoaffinity Probes for Target Identification and Discovering Protein Interaction Partners
Doug Johnson, PhD, Senior Director, Chemical Biology & Proteomics, Biogen

Boehringer Ingelheim
Targeting a New E3 Ligase
Lena Muenzker, PhD, Postdoctoral Fellow, Drug Discovery Sciences, Boehringer Ingelheim RCV GmbH & Co. KG

Bristol Myers Squibb
Structure and Dynamics of the Human ‘Marker of Self’ 5-Transmembrane Receptor CD47
Gustavo Fenalti, PhD, formerly Principal Scientist & Structural Biologist, Molecular Structure and Design, Bristol Myers Squibb Co.

Chemical Space Docking: Novel ROCK1 Kinase Inhibitors Found by Large-Scale Structure-Based Virtual Screening
Paul Beroza, PhD, Senior Principal Scientist, Computational Drug Discovery, Genentech, Inc.

Identification of Novel Macrocyclic Bactericidal Inhibitors Targeting the Essential Bacterial ABC Transporter MsbA
Christian N. Cunningham, PhD, Scientist, Early Discovery Biochemistry, Genentech, Inc.

Cellular Permeability of Cystine Knot Peptides
Rami N. Hannoush, PhD, formerly Group Leader, Early Discovery Biochemistry, Genentech, Inc.

High-Throughput Kinetic Characterization of Covalent Inhibitors of KRASG12C by Intact MS and Targeted MRM
Sherry Ke Li, PhD, Scientist, Biochemical & Cellular Pharmacology, Genentech, Inc.

Biophysical Approaches to Soften Hard Targets
John Quinn, PhD, Senior Principal Scientist, Biophysical Group, Biochemical and Cellular Pharmacology, Genentech, Inc.

Photoredox Reactions Applied to DNA-Encoded Libraries
Adam Csakai, PhD, Investigator, Discovery Chemistry, Encoded Libraries Technology, GlaxoSmithKline

Integration of High-Throughput PROTAC Synthesis and Direct to Biology Assaying for Rapidly Evaluating Targeted Protein Degradation
Afjal Miah, PhD, Associate Fellow, Protein Degradation, Medicinal Science & Technology, GlaxoSmithKline

Enterprise-Wide Predictive Model for Early Absorption, Distribution, Metabolism, and Excretion Properties
Renee DesJarlais, PhD, Scientific Director & Fellow, Janssen R&D LLC

Design of Highly Selective Salt-Inducible Kinase Inhibitors
Mark S. Tichenor, PhD, Senior Principal Scientist, Medicinal Chemistry, Janssen R&D LLC

Identification of PPI Inhibitors for NKG2D Reveals a Novel Cryptic Pocket with a Unique MoA
Aaron A. Thompson, PhD, Senior Scientist, Structural Biology, Janssen Pharmaceuticals Inc.

Quantitative Mechanistic Modeling of Covalent PROTACs
Charu Chaudhry, PhD, Senior Principal Scientist, Molecular Pharmacology, Janssen Pharmaceuticals Inc.

Macrocyclic Peptides to Target pan-KRAS and the Evolution of Permeability Mechanism
Chunhui Huang, PhD, Associate Principal Scientist, Discovery Chemistry, Merck Research Labs

A New FBDD Case Study
Jack D. Scott, PhD, Director, Discovery Chemistry, Merck

Discovery and Development of Recently FDA-Approved Asciminib (ABL001): A Fragment Origin Story
Wolfgang Jahnke, PhD, Director Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research

Identification of a Macrocyclic PCSK9 Peptide Ligand
Johannes Ottl, PhD, Director, Chemical Genetics & Encoded Library Technologies, Novartis Institutes for BioMedical Research

A Strategy to Assess the Cellular Activity of E3 Ligases against Neo-Substrates Using Electrophilic Probes
Claudio Thoma, PhD, Lab Head, Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Inc.

Development of Chemical Biology Probes for Applications in Drug Discovery
Christopher am Ende, PhD, Associate Research Fellow, Internal Medicine Medicinal Chemistry, Pfizer Inc.

Triage Strategies for DEL Screens: Toward Tractable Chemical Matter
Justin I. Montgomery, PhD, Associate Research Fellow, Discovery Sciences, Pfizer Inc.

Improved Efficiency in DEL Hit Confirmation
Anokha S. Ratnayake, PhD, Principal Scientist, Design and Synthesis Sciences, DNA Encoded Library Technology Group, Pfizer Global R&D Groton Laboratories

* As of 1/1/2022 – Please see individual agenda pages for most up-to-date list of speakers